profit from every $100 of sales.
$0$100
PROCEPT BioRobotics
$23.80+1.23% today
-16.2% in 1 year
1-year low $16.691-year high $36.10
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What PROCEPT BioRobotics sold, what it kept, and what it did with the cash.
Sales went from $75.0 million in 2022 to $308 million in 2025, with -$95.6 million of profit last year.
SalesProfit
PROCEPT BioRobotics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| PROCEPT BioRobotics | No profit yet | ||
 Boston Scientific | 22.2× · Fair price | ||
 Koninklijke Philips | 30.1× · Expensive | ||
 Steris | 32.8× · Expensive | ||
 Zimmer Biomet Holdings | 27.7× · Fair price |
AI analysis
An AI analyst reads PROCEPT BioRobotics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 75 | 136 | 224 | 308 | |
| 37 | 71 | 137 | 196 | |
| -81 | -109 | -97 | -104 | |
| -79 | -98 | -82 | -85 | |
| -87 | -106 | -91 | -96 | |
| -1.96 | -2.24 | -1.75 | -1.72 | |
| 49.4% | 52.2% | 61.1% | 63.7% | |
| -107.6% | -80.2% | -43.0% | -33.7% | |
| -116.2% | -77.8% | -40.7% | -31.0% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 309 | 405 | 534 | 508 |
| Cash | 222 | 257 | 334 | 287 |
| Total debt | 77 | 79 | 80 | 78 |
| Total liabilities | 112 | 124 | 132 | 142 |
| 197 | 281 | 402 | 366 | |
| 44 | 47 | 52 | 56 | |
| -23.6% | -22.3% | -14.2% | -16.3% | |
| -44.2% | -37.7% | -22.7% | -26.1% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -80 | -108 | -99 | -49 | |
| 3 | 25 | 4 | 9 | |
| -83 | -133 | -104 | -58 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 10 | 19 | 32 | 48 |
Valuation
- –
- –
- –
- 4.3×
- 4.4×
- –
- –
- -4.3%
- -7.0%
- 0.0%
Profitability
- 63.7%
- -33.7%
- -31.0%
- -31.8%
- -25.7%
- -24.3%
- -27.7%
- -21.0%
- -25.7%
- 22.7%
Growth
- +60.1%
- –
- +43.7%
- –
- +6.2%
Financial health
- -2.4×
- 0.15
- 10.6%
- -30.9×
- 6.73
- 5.51
- 0.66
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 16%of 952
Bottom 8%of 884
Top 9%of 886
Bottom 20%of 987
What analysts expect
- Average price target
- $44.50
- Range
- $30.00 – $62.00
- 3 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 29, 2026 | -0.56 | -0.55 | −1.8% |
| Feb 25, 2026 | -0.53 | -0.32 | −65.6% |
| Nov 4, 2025 | -0.38 | -0.41 | +7.3% |
| Aug 6, 2025 | -0.35 | -0.41 | +14.6% |
| Apr 24, 2025 | -0.45 | -0.49 | +8.2% |
| Feb 25, 2025 | -0.35 | -0.34 | −2.9% |
| Oct 28, 2024 | -0.40 | -0.48 | +16.7% |
| Aug 1, 2024 | -0.50 | -0.52 | +3.8% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
31No pass
Benjamin Graham
39No pass
Philip Fisher
47No pass
Peter Lynch
70Pass
Joel Greenblatt
0No pass
Charlie Munger
33No pass
Terry Smith
33No pass
Questions about PROCEPT BioRobotics
Is PROCEPT BioRobotics a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the PROCEPT BioRobotics AI analysis
What does PROCEPT BioRobotics do?
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It is in Medical - Devices.
Does PROCEPT BioRobotics pay a dividend?
No. PROCEPT BioRobotics does not pay a dividend at the moment.
Is PROCEPT BioRobotics stock halal?
Yes. PROCEPT BioRobotics passes our halal screen: its business is permitted and its debt is 6% of its market value, under the 30% limit. How we check
How has PROCEPT BioRobotics stock done over the past year?
Down 16.2% over the past twelve months, to $23.80. It traded between $16.69 and $36.10 and is 34.1% below its high.
Who are PROCEPT BioRobotics's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with PROCEPT BioRobotics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.